Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Pulmonary Arterial Hypertension (ORCHESTRA)
NCT02081690Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Evaluation of the Reliability and the Construct Validity of the Cardiopulmonary Symptoms Domain of the PAH-SYMPACT at Week 16, Evaluation of the Reliability and the Construct Validity of the Cardiovascular Symptoms Domain of the PAH-SYMPACT at Week 16 and 3 more. Started Mar 2014; status: terminated.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02081690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081690.